Key quarterly figures
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|
| Q2 Sales | Beat | $1.33 billion | $1.31 billion |
| Q2 Adjusted EPS | Miss | $0.51 | $0.54 |
| Q2 Loss Per Share | | $0.25 | |
| Q2 Net Loss | | $26.30 million | |
| Q2 Adjusted EBITDA | Beat | $166.60 million | $158.98 million |
Drivers of the quarter
- New product launches — The company said the launch of Bioniq GO and other new products in Europe and the U.S. contributed to topline growth.
- Regional performance — Strong sales growth in Asia Pacific and Latin America offset declines in EMEA and China.
- FX headwinds — The company said foreign exchange negatively impacted reported net sales and adjusted EBITDA.
- Gross margin pressure — Gross profit margin declined due to sales mix, higher costs, and inventory write-downs, partly offset by pricing benefits.
Quarterly results and guidance
HLF•
